 |
Relationships
|
Syntiron granted sanofi pasteur an exclusive world-wide license to its human vaccine against Staphylococcus aureus in December 2009. The agreement involves joint development of the product and includes an undisclosed initial licensing fee, milestone payments that could reach over $149 million dollars in total. Syntiron also stands to receive royalties on future net sales of the product.
|
|
In October 2008, Syntiron received a $4.1 million dollar contract from the US Defense Threat Reduction Agency (DTRA) for the development of vaccines to protect against three potential bacterial biowarfare agents, including Bacillus anthracis (anthrax), Yersinia pestis (plague), and Burkholderia pseudomallei (melioidosis). See the “Press Releases” page on the Syntiron website to learn more.
|
|
Since 2006, Syntiron has been awarded four Phase I National Institutes of Health (NIH) Small Business Innovation Research grants for the research and development of vaccines against Salmonella spp., Staphylococcus aureus, and Yersinia pestis. Syntiron recently submitted a Phase II application.
|
|
Syntiron holds an exclusive license of the Epitopix SRP® technology patent portfolio for all human vaccine applications. Epitopix has proven SRP Technology to be safe and effective in hundreds of millions of animals of various species.
|
|
Syntiron retains Robins, Kaplan, Miller & Ciresi, LLP (RKMC) as primary legal counsel. Mr. Ryan Miest is a partner at RKMC and serves as Corporate Attorney to Syntiron. Mr. Miest's practice focuses on representation of technology-driven enterprises ranging from start-ups to publicly-traded corporations in the areas of mergers and acquisitions, corporate finance and securities, strategic intellectual property monetization, and technology transactions.
|
|
Syntiron is pleased to have the US Medical Countermeasures and Vaccines Biological Defense Research Directorate Naval Medical Research Center group as a partner under its DTRA contract. Syntiron is currently investigating other new and potential biodefense vaccine and therapeutic projects which would also involve NMRC.
|
|
Syntiron’s close ties with the University of Minnesota have culminated in several scientific collaborations with professors, numerous synergistic business relationships with other companies and faculty, and career development opportunities for University students in the Syntiron laboratory. One of these collaborations includes the laboratory of Dr. Patrick Schlievert in the Department of Microbiology, Medical school. Dr. Schlievert’s laboratory is a world leader in the field of gram-positive pathogenesis and bacterial superantigens.
|
|
Syntiron is involved in ongoing scientific collaboration with Dr. Robert Perry of the Department of Microbiology and Immunology at the University of Kentucky. Dr. Perry’s laboratory studies the bacterium Yersinia pestis, the causative agent of bubonic and pneumonic plague.
|
|
Mr. Douglas Freitag is the President of Bayside Materials Technology, a company established in 1993 to help companies with federal business development, government affairs, and technology transition. Mr. Freitag serves as an Syntiron’s Washington advocate and has been an integral part in developing relationships with NIH, DTRA, NMRC and other important US government agencies.
|
|
B. T. McAllister Associates, Inc. is comprised of expert regulatory and quality assurance consultants. Syntiron has employed the services of Dr. Byron T. McAllister and his colleague, Mrs. Jan Zorn, to assist Syntiron in the licensing and commercialization of its vaccine products.
|
|
|
